Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. OSTEONECROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.3.1 DEMOGRAPHIC TRENDS: IMAPCTS ON ALL INCIDENCE RATES
4.3.2 PATIENT FLOW DIAGRAM
4.3.3 KEY PRICING STRATEGIES
4.4 HEALTHCARE ECONOMY
4.4.1 HEALTHCARE EXPENDITURE
4.4.2 CAPITAL EXPENDITURE
4.4.3 CAPEX TRENDS
4.4.4 CAPEX ALLOCATION
4.4.5 FUNDING SOURCES
4.4.6 INDUSTRY BENCHMARKS
4.4.7 GDP RATIO IN OVERALL GDP
4.4.8 HEALTHCARE SYSTEM STRUCTURE
4.4.9 GOVERNMENT POLICIES
4.4.10 ECONOMIC DEVELOPMENT
4.5 PIPELINE ANALYSIS
4.6 REIMBURSEMENT FRAMEWORK
4.7 TECHNOLOGY ROADMAP
4.8 VALUE CHAIN ANALYSIS
5 EPIDEMIOLOGY
6 REGULATIONS
6.1 REGULATORY APPROVAL PROCESS AND PATHWAYS:
6.2 LICENSING AND REGISTRATION:
6.3 POST-MARKETING SURVEILLANCE:
6.4 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES:
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING NUMBER OF TRAUMATIC INJURIES
7.1.2 INCREASING CONSUMPTION OF STEROIDS AND RELATED DRUGS
7.1.3 INCREASING INCIDENCE OF OSTEONECROSIS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE DIAGNOSIS AND TREATMENT OF OSTEONECROSIS
7.2.2 PROGNOSTIC AND DIAGNOSTIC CHALLENGES
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR OSTEONECROSIS
7.3.2 INCREASING REIMBURSEMENTS SCENARIOS
7.4 CHALLENGES
7.4.1 AVAILABILITY OF LIMITED TREATMENT OPTIONS
7.4.2 CHALLENGING LONG-TERM MANAGEMENT AND FOLLOW UP
8 U.S. OSTEONECROSIS MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 TRAUMATIC
8.3 NON-TRAUMATIC
8.4 IDIOPATHIC
9 U.S. OSTEONECROSIS MARKET, BY TYPE
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 SURGERY
9.2.1.1 CORE DECOMPRESSION
9.2.1.2 BONE RESHAPING (OSTEOTOMY)
9.2.1.3 BONE TRANSPLANT
9.2.1.4 JOINT REPLACEMENT THERAPY
9.2.1.5 STEM CELL THERAPY
9.2.2 MEDICATION
9.2.2.1 NSAIDS
9.2.2.1.1 IBUPROFEN
9.2.2.1.2 ASPIRIN
9.2.2.1.3 NAPROXEN
9.2.2.1.4 DICLOFENAC
9.2.2.1.5 OTHERS
9.2.2.2 BLOOD THINNERS
9.2.2.2.1 WARFARIN
9.2.2.2.2 HEPARIN
9.2.2.2.3 ENOXAPARIN
9.2.2.2.4 ARGATROBAN
9.2.2.2.5 DICOUMARAL
9.2.2.2.6 FONDAPARINUX
9.2.2.2.7 XIMELAGATRAN
9.2.2.3 OSTEOPOROSIS DRUGS
9.2.2.3.1 ALENDRONATE
9.2.2.3.2 RISEDRONATE
9.2.2.3.3 IBANDRONATE
9.2.2.3.4 ZOLEDRONIC ACID
9.2.2.3.5 DENOSUMAB
9.2.2.3.6 OTHERS
9.2.2.4 CHOLESTEROL-LOWERING DRUGS
9.2.2.4.1 ATORVASTATIN
9.2.2.4.2 PRAVASTATIN
9.2.2.4.3 FLUVASTATIN
9.2.2.4.4 ROSUVASTATIN
9.2.2.4.5 SIMVASTATIN
9.2.2.4.6 PITAVASTATIN
9.2.2.4.7 LOVASTATIN
9.2.2.5 OTHERS
9.2.3 PHYSICAL THERAPY
9.2.3.1 CRUTCHES
9.2.3.1.1 AXILLA CRUTCHES
9.2.3.1.1.1 METAL ALLOY
9.2.3.1.1.2 WOOD
9.2.3.1.1.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE
9.2.3.1.1.4 OTHERS
9.2.3.1.2 ELBOW CRUTCHES
9.2.3.1.2.1 OPEN-CUFF ELBOW CRUTCHES
9.2.3.1.2.1.1 METAL ALLOY
9.2.3.1.2.1.2 WOOD
9.2.3.1.2.1.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE
9.2.3.1.2.1.4 OTHERS
9.2.3.1.2.2 CLOSED-CUFF ELBOW CRUTCHES
9.2.3.1.2.2.1 METAL ALLOY
9.2.3.1.2.2.2 WOOD
9.2.3.1.2.2.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE
9.2.3.1.2.2.4 OTHERS
9.2.3.1.3 GUTTER CRUTCHES
9.2.3.1.3.1 METAL ALLOY
9.2.3.1.3.2 WOOD
9.2.3.1.3.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE
9.2.3.1.3.4 OTHERS
9.2.3.2 CASTING AND BRACING
9.2.3.2.1 NEWINGTON BRACE
9.2.3.2.2 TORONTO ORTHOSIS
9.2.3.2.3 SCOTTISH RITE ORTHOSIS
9.2.3.2.4 BROOMSTICK PLASTERS
9.2.3.2.5 BIRMINGHAM ORTHOSIS
9.2.3.3 OTHERS
9.2.3.3.1 CONVENTIONAL CALIPERS
9.2.3.3.2 SNYDER SLINGS
9.2.3.3.3 SLINGS WITH CRUTCHES
9.2.3.3.4 TRACTION
9.2.3.3.5 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.1.1 CLOSED BORE
9.3.1.1.1.1 LOW FIELD STRENGTH
9.3.1.1.1.2 MID FIELD STRENGTH
9.3.1.1.1.3 HIGH FIELD STRENGTH
9.3.1.1.2 OPEN BORE
9.3.1.1.2.1 LOW FIELD STRENGTH
9.3.1.1.2.2 MID FIELD STRENGTH
9.3.1.1.2.3 HIGH FIELD STRENGTH
9.3.1.2 COMPUTED TOMOGRAPHY SCANNING
9.3.1.2.1 HIGH END SLICE
9.3.1.2.2 MID END SLICE
9.3.1.2.3 LOW END SLICE
9.3.1.2.4 CONE BEAN
9.3.1.3 X-RAY IMAGING
9.3.1.3.1 RADIOGRAPHY
9.3.1.3.1.1 DIGITAL IMAGING
9.3.1.3.1.2 FILM-BASED IMAGING
9.3.1.3.2 FLUOROSCOPY
9.3.1.3.2.1 DIGITAL IMAGING
9.3.1.3.2.2 FILM-BASED IMAGING
9.3.1.3.3 OTHERS
9.3.1.4 OTHERS
9.3.1.4.1 BONE SCAN
9.3.1.4.2 ULTRASOUND
9.3.1.4.2.1 2D ULTRASOUND
9.3.1.4.2.1.1 B/W ULTRASOUND
9.3.1.4.2.1.2 COLOURED
9.3.1.4.2.2 DOPPLER ULTRASOUND
9.3.1.4.2.2.1 B/W ULTRASOUND
9.3.1.4.2.2.2 COLOURED
9.3.1.4.2.3 3D & 4D ULTRASOUND
9.3.1.4.2.3.1 B/W ULTRASOUND
9.3.1.4.2.3.2 COLOURED
9.3.1.4.3 OTHERS
9.3.2 BIOPSY
9.3.2.1 NEEDLE BIOPSY
9.3.2.2 OPEN BIOPSY
9.3.2.3 OTHERS
9.3.3 OTHERS
10 U.S. OSTEONECROSIS MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE 2
10.3 STAGE 3
10.4 STAGE 4
10.5 STAGE 1
11 U.S. OSTEONECROSIS MARKET, BY LOCATION
11.1 OVERVIEW
11.2 OSTEONECROSIS OF HIP/FEMORAL HEAD OSTEONECROSIS
11.2.1 TRAUMATIC
11.2.2 NON-TRAUMATIC
11.2.3 IDIOPATHIC OSTEONECROSIS
11.2.3.1 LEGG-CALVE-PERTHES DISEASE
11.2.3.1.1 TREATMENT
11.2.3.1.1.1 NON-SURGICAL
11.2.3.1.1.1.1 ANTI-INFLAMMATORY MEDICATION
11.2.3.1.1.1.1.1 IBUPROFEN
11.2.3.1.1.1.1.2 ASPIRIN
11.2.3.1.1.1.1.3 NAPROXEN SODIUM
11.2.3.1.1.1.1.4 NABUMETONE
11.2.3.1.1.1.1.5 OTHERS
11.2.3.1.1.1.2 BISPHOSPHONATES MEDICATIONS
11.2.3.1.1.1.2.1 ALENDRONATE
11.2.3.1.1.1.2.2 RISEDRONATE
11.2.3.1.1.1.2.3 IBANDRONATE
11.2.3.1.1.1.2.4 ZOLEDRONIC ACID
11.2.3.1.1.1.2.5 PAMIDRONATE
11.2.3.1.1.1.2.6 OTHERS
11.2.3.1.1.1.3 CRUTCHES
11.2.3.1.1.1.3.1 AXILLA CRUTCHES
11.2.3.1.1.1.3.2 ELBOW CRUTCHES
11.2.3.1.1.1.3.3 GUTTER CRUTCHES
11.2.3.1.1.1.4 CASTINGS & BRACINGS
11.2.3.1.1.1.4.1 NEWINGTON BRACE
11.2.3.1.1.1.4.2 TORONTO ORTHOSIS
11.2.3.1.1.1.4.3 SCOTTISH RITE ORTHOSIS
11.2.3.1.1.1.4.4 BROOMSTICK PLASTERS
11.2.3.1.1.1.4.5 BIRMINGHAM ORTHOSIS
11.2.3.1.1.2 SURGICAL
11.2.3.1.1.2.1 FEMORAL OSTEOTOMY
11.2.3.1.1.2.1.1 FEMORAL DEROTATION OSTEOTOMY
11.2.3.1.1.2.1.2 VARUS DEROTATION OSTEOTOMY
11.2.3.1.1.2.2 INNOMINATE OSTEOTOMY
11.2.3.1.1.2.2.1 SALTER (SINGLE INNOMINATE OSTEOTOMY)
11.2.3.1.1.2.2.2 SUTHERLAND (DOUBLE INNOMINATE OSTEOTOMY)
11.2.3.1.1.2.2.3 STEEL, TONNIS OR CARLOS (TRIPLE INNOMINATE OSTEOTOMY)
11.2.3.1.1.2.2.4 GANZ (PERIACETABULAR)
11.2.3.1.1.2.3 SHELF ARTHROPLASTY
11.2.3.1.1.2.4 OTHERS
11.2.3.1.2 DIAGNOSIS
11.2.3.1.2.1 MAGNETIC RESONANCE IMAGING (MRI)
11.2.3.1.2.1.1 CLOSED BORE
11.2.3.1.2.1.1.1 LOW FIELD STRENGTH
11.2.3.1.2.1.1.2 MID FIELD STRENGTH
11.2.3.1.2.1.1.3 HIGH FIELD STRENGTH
11.2.3.1.2.1.2 OPEN BORE
11.2.3.1.2.1.2.1 LOW FIELD STRENGTH
11.2.3.1.2.1.2.2 MID FIELD STRENGTH
11.2.3.1.2.1.2.3 HIGH FIELD STRENGTH
11.2.3.1.2.2 COMPUTED TOMOGRAPHY SCANNING
11.2.3.1.2.2.1 HIGH END SLICE
11.2.3.1.2.2.2 MID END SLICE
11.2.3.1.2.2.3 LOW END SLICE
11.2.3.1.2.2.4 CONE BEAN
11.2.3.1.2.3 X-RAY IMAGING
11.2.3.1.2.3.1 RADIOGRAPHY
11.2.3.1.2.3.1.1 DIGITAL IMAGING
11.2.3.1.2.3.1.2 FILM-BASED IMAGING
11.2.3.1.2.3.2 FLUOROSCOPY
11.2.3.1.2.3.2.1 DIGITAL IMAGING
11.2.3.1.2.3.2.2 FILM-BASED IMAGING
11.2.3.1.2.3.3 OTHERS
11.2.3.1.2.4 OTHERS
11.2.3.2 OTHERS
11.3 OSTEONECROSIS OF THE KNEE
11.3.1 TRAUMATIC
11.3.2 NON-TRAUMATIC
11.3.3 IDIOPATHIC OSTEONECROSIS
11.4 OSTEONECROSIS OF THE SHOULDER
11.4.1 TRAUMATIC
11.4.2 NON-TRAUMATIC
11.4.3 IDIOPATHIC OSTEONECROSIS
11.5 OSTEONECROSIS OF THE TALUS
11.5.1 TRAUMATIC
11.5.2 NON-TRAUMATIC
11.5.3 IDIOPATHIC OSTEONECROSIS
11.6 OSTEONECROSIS OF THE LUNATE
11.6.1 TRAUMATIC
11.6.2 NON-TRAUMATIC
11.6.3 IDIOPATHIC OSTEONECROSIS
11.7 OSTEONECROSIS OF THE SCAPHOID
11.7.1 TRAUMATIC
11.7.2 NON-TRAUMATIC
11.7.3 IDIOPATHIC OSTEONECROSIS
11.8 OTHERS
12 U.S. OSTEONECROSIS MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 ORAL
12.2.1.1 TABLETS
12.2.1.2 CAPSULES
12.2.2 PARENTERAL
12.2.3 OTHERS
12.3 GENERIC
12.3.1 ORAL
12.3.1.1 TABLETS
12.3.1.2 CAPSULES
12.3.2 PARENTERAL
12.3.3 OTHERS
13 U.S. OSTEONECROSIS MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 PRESCRIBED DRUGS
13.3 OVER THE COUNTER DRUGS
14 U.S. OSTEONECROSIS MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.3 FEMALE
15 U.S. OSTEONECROSIS MARKET, BY AGE
15.1 OVERVIEW
15.2 ADULT
15.3 GERIATRIC
15.4 CHILDREN
16 U.S. OSTEONECROSIS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 PUBLIC
16.2.2 PRIVATE
16.3 ORTHOPEDIC CLINICS
16.4 SPECIALTY CLINICS
16.5 AMBULATORY CENTERS
16.6 OTHERS
17 U.S. OSTEONECROSIS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 HOSPITAL PHARMACY
17.2.2 RETAIL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 U.S. OSTEONECROSIS MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: U.S.
19 SWOT ANALYSIS
20 U.S. OSTEONECROSIS MARKET, CPS
20.1 TEVA PHARMACEUTICALS USA, INC. (SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.2 PFIZER INC. (2022)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 BAYER AG (2022)
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENT
20.4 STRYKER
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 ARTHREX, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 PRODUCT PORTFOLIO
20.5.3 RECENT DEVELOPMENT
20.6 ALMATICA PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 DR. REDDY'S LABORATORIES LTD. (2022)
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 HALEON GROUP OF COMPANIES
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 SCIEGEN PHARMACEUTICALS.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 ZIMMER BIOMET
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 COST OF OSTEONECROSIS TREATMENT SURGERIES
TABLE 2 U.S. OSTEONECROSIS MARKET, PIPELINE ANALYSIS
TABLE 3 U.S. OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 U.S. OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 U.S. TREATMENT IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 U.S. SURGERY IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 7 U.S. MEDICATION IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 8 U.S. NSAIDS IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 9 U.S. BLOOD THINNERS IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 10 U.S. OSTEOPOROSIS DRUGS IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 11 U.S. CHOLESTEROL-LOWERING DRUGS IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 12 U.S. PHYSICAL THERAPY IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 13 U.S. CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 14 U.S. AXILLA CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 15 U.S. ELBOW CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 16 U.S. OPEN-CUFF ELBOW CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 17 U.S. CLOSED-CUFF ELBOW CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 18 U.S. GUTTER CRUTCHES IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 19 U.S. CASTING AND BRACING IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 20 U.S. OTHERS IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 21 U.S. DIAGNOSIS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 U.S. IMAGING TEST IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 U.S. CLOSED BORE IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 U.S. OPEN BORE IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 U.S. COMPUTED TOMOGRAPHY SCANNING IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 27 U.S. X-RAY IMAGING IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 U.S. RADIOGRAPHY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 U.S. FLUOROSCOPY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 U.S. OTHERS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 U.S. ULTRASOUND IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 32 U.S. 2D ULTRASOUND IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 U.S. DOPPLER ULTRASOUND IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 34 U.S. 3D & 4D ULTRASOUND IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 35 U.S. BIOPSY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 U.S. OSTEONECROSIS MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 37 U.S. OSTEONECROSIS MARKET, BY LOCATION, 2021-2030 (USD THOUSAND)
TABLE 38 U.S. OSTEONECROSIS OF HIP/FEMORAL HEAD OSTEONECROSIS IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 U.S. IDIOPATHIC OSTEONECROSIS IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 U.S. LEGG-CALVE-PERTHES DISEASE IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 U.S. TREATMENT IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 U.S. NON-SURGICAL IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 U.S. ANTI-INFLAMMATORY MEDICATIONS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 U.S. BISPHOSPHONATES MEDICATIONS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 U.S. CRUTCHES IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 U.S. CASTING AND BRACING IN OSTEONECROSIS MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)
TABLE 47 U.S. SURGICAL IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 U.S. FEMORAL OSTEOTOMY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 U.S. INNOMINATE OSTEOTOMY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 U.S. DIAGNOSIS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 U.S. CLOSED BORE IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 U.S. OPEN BORE IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 U.S. COMPUTED TOMOGRAPHY SCANNING IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 U.S. X-RAY IMAGING IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 U.S. RADIOGRAPHY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 U.S. FLUOROSCOPY IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 U.S. OSTEONECROSIS OF THE KNEE IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 U.S. OSTEONECROSIS OF THE SHOULDER IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.S. OSTEONECROSIS OF THE TALUS IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.S. OSTEONECROSIS OF THE LUNATE IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.S. OSTEONECROSIS OF THE SCAPHOID IN OSTEONECROSIS MARKET, BY DISEASE TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.S. OSTEONECROSIS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.S. BRANDED IN OSTEONECROSIS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 U.S. ORAL IN OSTEONECROSIS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.S. GENERIC IN OSTEONECROSIS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.S. ORAL IN OSTEONECROSIS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.S. OSTEONECROSIS MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 69 U.S. OSTEONECROSIS MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 70 U.S. OSTEONECROSIS MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 U.S. OSTEONECROSIS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 U.S. HOSPITALS IN OSTEONECROSIS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 U.S. OSTEONECROSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 74 U.S. RETAIL SALES IN OSTEONECROSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
List of Figure
FIGURE 1 U.S. OSTEONECROSIS MARKET: SEGMENTATION
FIGURE 2 U.S. OSTEONECROSIS MARKET: DATA TRIANGULATION
FIGURE 3 U.S. OSTEONECROSIS MARKET: DROC ANALYSIS
FIGURE 4 U.S. OSTEONECROSIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. OSTEONECROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. OSTEONECROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. OSTEONECROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 U.S. OSTEONECROSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 U.S. OSTEONECROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. OSTEONECROSIS MARKET: SEGMENTATION
FIGURE 11 INCREASING NUMBER OF TRAUMATIC INJURIES IS EXPECTED TO DRIVE THE GROWTH OF THE U.S. OSTEONECROSIS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE TRAUMATIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. OSTEONECROSIS MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET
FIGURE 14 U.S. OSTEONECROSIS MARKET: BY DISEASE TYPE, 2022
FIGURE 15 U.S. OSTEONECROSIS MARKET: BY DISEASE TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 U.S. OSTEONECROSIS MARKET: BY DISEASE TYPE, CAGR (2023-2030)
FIGURE 17 U.S. OSTEONECROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 18 U.S. OSTEONECROSIS MARKET: BY TYPE, 2022
FIGURE 19 U.S. OSTEONECROSIS MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 U.S. OSTEONECROSIS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 U.S. OSTEONECROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 U.S. OSTEONECROSIS MARKET: BY STAGES, 2022
FIGURE 23 U.S. OSTEONECROSIS MARKET: BY STAGES, 2023-2030 (USD THOUSAND)
FIGURE 24 U.S. OSTEONECROSIS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 25 U.S. OSTEONECROSIS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 26 U.S. OSTEONECROSIS MARKET: BY LOCATION, 2022
FIGURE 27 U.S. OSTEONECROSIS MARKET: BY LOCATION, 2023-2030 (USD THOUSAND)
FIGURE 28 U.S. OSTEONECROSIS MARKET: BY LOCATION, CAGR (2023-2030)
FIGURE 29 U.S. OSTEONECROSIS MARKET: BY LOCATION, LIFELINE CURVE
FIGURE 30 U.S. OSTEONECROSIS MARKET: BY DRUG TYPE, 2022
FIGURE 31 U.S. OSTEONECROSIS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 32 U.S. OSTEONECROSIS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 U.S. OSTEONECROSIS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 U.S. OSTEONECROSIS MARKET: BY PRESCRIPTION, 2022
FIGURE 35 U.S. OSTEONECROSIS MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 36 U.S. OSTEONECROSIS MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 37 U.S. OSTEONECROSIS MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 38 U.S. OSTEONECROSIS MARKET: BY GENDER, 2022
FIGURE 39 U.S. OSTEONECROSIS MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 40 U.S. OSTEONECROSIS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 41 U.S. OSTEONECROSIS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 42 U.S. OSTEONECROSIS MARKET: BY AGE, 2022
FIGURE 43 U.S. OSTEONECROSIS MARKET: BY AGE, 2023-2030 (USD THOUSAND)
FIGURE 44 U.S. OSTEONECROSIS MARKET: BY AGE, CAGR (2023-2030)
FIGURE 45 U.S. OSTEONECROSIS MARKET: BY AGE, LIFELINE CURVE
FIGURE 46 U.S. OSTEONECROSIS MARKET: BY END USER, 2022
FIGURE 47 U.S. OSTEONECROSIS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 48 U.S. OSTEONECROSIS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 49 U.S. OSTEONECROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 U.S. OSTEONECROSIS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 51 U.S. OSTEONECROSIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 52 U.S. OSTEONECROSIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 53 U.S. OSTEONECROSIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 U.S. OSTEONECROSIS MARKET: COMPANY SHARE 2022 (%)
